Imperial College London

Professor Paul M. Matthews

Faculty of MedicineDepartment of Medicine

Edmond and Lily Safra Chair and Head of Brain Sciences



+44 (0)20 7594 2855p.matthews




Ms Siobhan Dillon +44 (0)20 7594 2855




E502Burlington DanesHammersmith Campus






BibTex format

author = {Gafson, A and Kicheol, K and Cencioni, M and Van, Hecke W and Nicholas, R and Baranzini, S and Matthews, P},
doi = {10.1212/NXI.0000000000000470},
journal = {Neurology, Neuroimmunology and Neuroinflammation},
title = {Mononuclear cell transcriptome changes associated with dimethyl fumarate in multiple sclerosis.},
url = {},
volume = {5},
year = {2018}

RIS format (EndNote, RefMan)

AB - Objective To identify short-term changes in gene expression in peripheral blood mononuclear cells (PBMCs) associated with treatment response to dimethyl fumarate (DMF, Tecfidera) in patients with relapsing-remitting MS (RRMS).Methods Blood samples were collected from 24 patients with RRMS (median Expanded Disability Status Scale score, 2.0; range 1–7) at baseline, 6 weeks, and 15 months after the initiation of treatment with DMF (BG-12; Tecfidera). Seven healthy controls were also recruited, and blood samples were collected over the same time intervals. PBMCs were extracted from blood samples and sequenced using next-generation RNA sequencing. Treatment responders were defined using the composite outcome measure “no evidence of disease activity” (NEDA-4). Time-course and cross-sectional differential expression analyses were performed to identify transcriptomic markers of treatment response.Results Treatment responders (NEDA-4 positive, 8/24) over the 15-month period had 478 differentially expressed genes (DEGs) 6 weeks after the start of treatment. These were enriched for nuclear factor (erythroid-derived 2)-like 2 (Nrf2) and inhibition of nuclear factor κB (NFκB) pathway transcripts. For patients who showed signs of disease activity, there were no DEGs at 6 weeks relative to their (untreated) baseline. Contrasting transcriptomes expressed at 6 weeks with those at 15 months of treatment, 0 and 1,264 DEGs were found in the responder and nonresponder groups, respectively. Transcripts in the nonresponder group (NEDA-4 negative, 18/24) were enriched for T-cell signaling genes.Conclusion Short-term PBMC transcriptome changes reflecting activation of the Nrf2 and inhibition of NFκB pathways distinguish patients who subsequently show a medium-term treatment response with DMF. Relative stabilization of gene expression patterns may accompany treatment-associated suppression of disease activity.
AU - Gafson,A
AU - Kicheol,K
AU - Cencioni,M
AU - Van,Hecke W
AU - Nicholas,R
AU - Baranzini,S
AU - Matthews,P
DO - 10.1212/NXI.0000000000000470
PY - 2018///
SN - 2332-7812
TI - Mononuclear cell transcriptome changes associated with dimethyl fumarate in multiple sclerosis.
T2 - Neurology, Neuroimmunology and Neuroinflammation
UR -
UR -
VL - 5
ER -